Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

Abstract:

:A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer Institute trials. An interim analysis of the Royal Marsden Hospital trial did not detect a preventive effect. The Italian trial concurred with the Royal Marsden Hospital trial. In contrast, the larger NSABP study detected a 49% reduction in the incidence of breast cancer with tamoxifen chemoprevention. Possible reasons for the different results are examined and the implications for tamoxifen chemoprevention are discussed.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Ross PJ,Powles TJ

doi

10.3816/CBC.2001.n.008

keywords:

subject

Has Abstract

pub_date

2001-04-01 00:00:00

pages

33-6; discussion 37-40

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)70317-2

journal_volume

2

pub_type

杂志文章,评审
  • A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

    abstract:BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.02.006

    authors: Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

    更新日期:2019-06-01 00:00:00

  • Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

    abstract:BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.035

    authors: Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

    更新日期:2006-08-01 00:00:00

  • A Survey of Breast Pathologists' Practice in Staging Multiple Foci of Invasive Carcinoma.

    abstract:BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.11.018

    authors: Wu JM,Turashvili G

    更新日期:2020-12-05 00:00:00

  • New horizons in treating metastatic disease.

    abstract::The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2001.n.002

    authors: Cristofanilli M,Hortobagyi GN

    更新日期:2001-01-01 00:00:00

  • Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

    abstract:BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.03.007

    authors: Balduzzi A,Bagnardi V,Sandri MT,Dellapasqua S,Cardillo A,Montagna E,Cancello G,Iorfida M,Ghisini R,Viale G,Intra M,Luini A,Goldhirsch A,Colleoni M

    更新日期:2015-10-01 00:00:00

  • Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.

    abstract:PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2013.10.013

    authors: Luu T,Frankel P,Chung C,Chow W,Mortimer J,Hurria A,Somlo G

    更新日期:2014-04-01 00:00:00

  • Development and Validation of a Preoperative Scoring System to Distinguish Between Nonadvanced and Advanced Axillary Lymph Node Metastasis in Patients With Early-stage Breast Cancer.

    abstract:BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.11.008

    authors: Murata T,Watase C,Shiino S,Jimbo K,Iwamoto E,Yoshida M,Takayama S,Suto A

    更新日期:2020-11-17 00:00:00

  • Cardiac toxicity of ErbB2-targeted therapies: what do we know?

    abstract::The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2008.s.007

    authors: Perez EA

    更新日期:2008-03-01 00:00:00

  • Taxanes and capecitabine in combination: rationale and clinical results.

    abstract::The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2002.n.004

    authors: Maher JF,Villalona-Calero MA

    更新日期:2002-01-01 00:00:00

  • Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.

    abstract::The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2020.01.002

    authors: Xu M,Yuan Y,Yan P,Jiang J,Ma P,Niu X,Ma S,Cai H,Yang K

    更新日期:2020-08-01 00:00:00

  • The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.

    abstract:BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.05.007

    authors: Escott CE,Zaenger D,Switchencko JM,Lin JY,Abugideiri M,Arciero CA,Pfister NT,Xu KM,Meisel JL,Subhedar P,Torres M,Curran WJ,Patel PR

    更新日期:2020-12-01 00:00:00

  • Review of Novel Sentinel Lymph Node Biopsy Techniques in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

    abstract::Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biop...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2018.01.004

    authors: Ersoy YE,Kadioglu H

    更新日期:2018-08-01 00:00:00

  • Digital mammography: a review of technical development and clinical applications.

    abstract::For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2003.n.013

    authors: Shah AJ,Wang J,Yamada T,Fajardo LL

    更新日期:2003-04-01 00:00:00

  • Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.

    abstract:BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.11.001

    authors: Strada MR,Palumbo R,Bernardo A,Riccardi A,Teragni C,Poggi G,Frascaroli M,Amatu A,Montagna B,Sottotetti F,Tagliaferri B,Bernardo G

    更新日期:2012-02-01 00:00:00

  • The Role of Contrast-Enhanced Ultrasound in the Diagnosis and Pathologic Response Prediction in Breast Cancer: A Meta-analysis and Systematic Review.

    abstract:PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.002

    authors: Zhou SC,Le J,Zhou J,Huang YX,Qian L,Chang C

    更新日期:2020-08-01 00:00:00

  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

    abstract:INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.11.018

    authors: Hull LE,Lynch JA,Berse BB,DuVall SL,Chun DS,Venne VL,Efimova OV,Icardi MS,Kelley MJ

    更新日期:2018-04-01 00:00:00

  • Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?

    abstract:OBJECTIVE:The Hungarian National Institute of Oncology has just closed a single-center randomized clinical study. The Optimal Treatment of the Axilla-Surgery or Radiotherapy (OTOASOR) trial compares completion axillary lymph node dissection (cALND) with regional nodal irradiation (RNI) in patients with sentinel lymph n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.04.004

    authors: Sávolt A,Polgár C,Musonda P,Mátrai Z,Rényi-Vámos F,Tóth L,Kásler M,Péley G

    更新日期:2013-10-01 00:00:00

  • Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.

    abstract::Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.029

    authors: Robson M

    更新日期:2004-10-01 00:00:00

  • Timing of Postmastectomy Reconstruction Does Not Impair Breast Cancer-Specific Survival: A Population-Based Study.

    abstract:BACKGROUND:Debate remains over the optimal timing of breast reconstruction after mastectomy. Immediate reconstruction has demonstrated superior psychosocial and aesthetic outcomes, but might delay adjuvant therapy. Conversely, delayed reconstruction allows for timely initiation of adjuvant therapy, but with potentially...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.003

    authors: Bezuhly M,Wang Y,Williams JG,Sigurdson LJ

    更新日期:2015-12-01 00:00:00

  • Breast cancer in adolescent and young adult women.

    abstract::Breast cancer is one of the most frequently diagnosed malignancy among adolescent and young adult (AYA) women, accounting for approximately 14% of all AYA cancer diagnoses and 7% of all breast cancer. Breast cancer in AYA women is believed to represent a more biologically aggressive disease, but aside from commonly kn...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2014.06.002

    authors: Gewefel H,Salhia B

    更新日期:2014-12-01 00:00:00

  • Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.

    abstract::Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.s.006

    authors: Mamounas EP,Geyer CE Jr,Swain SM

    更新日期:2004-01-01 00:00:00

  • Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.

    abstract:BACKGROUND:Ovarian suppression from chemotherapy results in bone loss in premenopausal women with breast cancer (BC). Less is known about bone microarchitecture changes. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure volumetric bone density and trabecular and cortical microarch...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.12.001

    authors: Hopson MB,Onishi M,Awad D,Buono D,Maurer M,Crew KD,Shane E,Hershman DL,Kalinsky K

    更新日期:2020-06-01 00:00:00

  • The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.

    abstract:BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2011.n.006

    authors: Itakura K,Lessing J,Sakata T,Heinzerling A,Vriens E,Wisner D,Alvarado M,Esserman L,Ewing C,Hylton N,Hwang ES

    更新日期:2011-03-01 00:00:00

  • Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer.

    abstract:BACKGROUND:Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we use...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.11.001

    authors: Mainwaring W,Bowers J,Pham N,Pezzi T,Shukla M,Bonnen M,Ludwig M

    更新日期:2019-04-01 00:00:00

  • Use of Adjuvant Breast Hypofractionation Radiation Treatment at a Cancer Center in Ontario From 2011 to 2018.

    abstract:BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.006

    authors: Lam E,Chan S,Karam I,Lee J,Wong G,Zhang L,Vesprini D,Wronski M,Chin L,Razvi Y,McKenzie E,Rakovitch E,Chow E

    更新日期:2020-10-01 00:00:00

  • Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer.

    abstract:BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2011.09.002

    authors: Chadha M,Vongtama D,Friedmann P,Parris C,Boolbol SK,Woode R,Harrison LB

    更新日期:2012-02-01 00:00:00

  • Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer.

    abstract:INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.10.011

    authors: Murphy BL,Boughey JC,Hieken TJ

    更新日期:2017-07-01 00:00:00

  • Tamoxifen-induced hot flashes.

    abstract::Hot flashes are the most prominent side effect of tamoxifen, the most frequently prescribed antitumor agent in the world. Little detailed information is available to predict who will develop hot flashes on tamoxifen, to describe the natural history of these hot flashes, and/or to predict who will request therapy for s...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/cbc.2000.n.004

    authors: Loprinzi CL,Zahasky KM,Sloan JA,Novotny PJ,Quella SK

    更新日期:2000-04-01 00:00:00

  • Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence.

    abstract::The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2008.n.038

    authors: Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

    更新日期:2008-08-01 00:00:00

  • Mammography Coverage and Tumor Stage in the Opportunistic Screening Context.

    abstract:INTRODUCTION:The increment of breast cancer screening coverage should lead to an increase in the proportion of early tumors diagnosed and the decrease of the cancer-related mortality. However, the effectiveness of opportunistic mammography screening is not well documented for public health systems in middle-income coun...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.04.014

    authors: Magario MB,Poli-Neto OB,Tiezzi DG,Angotti Carrara HH,Moreira de Andrade J,Candido Dos Reis FJ

    更新日期:2019-12-01 00:00:00